EGFR mutations are also crucial in NSCLC, because more than 60% of patients diagnosed with NSCLC harbor EGFR mutations, and treatment with tyrosine kinase inhibitors (TKIs) is preferred over chemotherapy or immunotherapy for these subset of patients [69,70]. Here, EGFR is linked to non-small cell lung carcinoma.